# A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Source: https://onco.cc/trials/nct06668103/  
OnCo record `nct06668103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ABSK043 in combination with Firmonertinib in non-small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.

## Summary

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib is a phase 2 interventional study registered as NCT06668103 by Abbisko Therapeutics Co, Ltd, with 54 participants planned, started 2024-11-25 and due to reach its primary completion in 2027-12-30. Interventions recorded: ABSK043 in combination with Firmonertinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06668103
- Phase: 2
- Setting: A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of ABSK043 Combined With Firmonertinib in Patients With EGFR Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer(NSCLC)
- Sponsor: Abbisko Therapeutics Co, Ltd
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT06668103: https://clinicaltrials.gov/study/NCT06668103

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/)

---
JSON: https://onco.cc/api/v1/entities/nct06668103.json